Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients (IONIA-E)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00697073
Recruitment Status : Completed
First Posted : June 13, 2008
Results First Posted : August 4, 2011
Last Update Posted : June 4, 2013
Information provided by (Responsible Party):
Santhera Pharmaceuticals

June 11, 2008
June 13, 2008
June 7, 2011
August 4, 2011
June 4, 2013
July 2008
May 2010   (Final data collection date for primary outcome measure)
Change in ICARS [ Time Frame: baseline and 12 months ]

International Cooperative Ataxia Rating Scale (ICARS):

ICARS consists of a one-hundred-point semi-quantitative scale based upon 19 simple testing manoeuvres compartmentalized into postural and stance disorders, limb ataxia, dysarthria and oculomotor disorders and has been previously used in this patient population with good inter-rater reliability.

Scores for each subscale quantify the extent of ataxia in each clinically important area. Subscale scores are summed to give a total score ranging from 0 (best) to 100 (worst).

  • Hematology [ Time Frame: 12 months ]
  • Nature and frequency of AEs [ Time Frame: 12 months ]
  • Blood and urine chemistry [ Time Frame: 12 months ]
  • Physical/neurological examination and vital signs [ Time Frame: 12 months ]
  • Electrocardiograms (ECGs) [ Time Frame: 12 months ]
Complete list of historical versions of study NCT00697073 on Archive Site
  • FARS (Friedreich's Ataxia Rating Scale) [ Time Frame: baseline and 12 Months ]
  • Nature and Frequency of Adverse Events [ Time Frame: 12 Months ]
  • FARS [ Time Frame: 12 Months ]
  • ICARS [ Time Frame: 12 Months ]
  • FACT [ Time Frame: 12 Months ]
Not Provided
Not Provided
Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients
A Phase III Open-Label, Single Group Extension Study of the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients
This study is meant to assess the safety and tolerability of idebenone in patients with Friedreich's Ataxia over a 12 months period.
The study involves 6 clinic visits.
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Friedreich's Ataxia
Drug: Idebenone
Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients > 45 kg/99 lbs: idebenone 2250 mg/day
Experimental: 1
high dose Idebenone
Intervention: Drug: Idebenone
Meier T, Perlman SL, Rummey C, Coppard NJ, Lynch DR. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J Neurol. 2012 Feb;259(2):284-91. doi: 10.1007/s00415-011-6174-y. Epub 2011 Jul 22.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
May 2010
May 2010   (Final data collection date for primary outcome measure)

Inclusion criteria:

  • Friedreich's ataxia patients completing core study SNT-III-002 (NCT00537680) and presenting at Week 24 (Visit 5) of that study
  • Body weight ≥ 25kg/55 lbs
  • Negative urine pregnancy test
  • Patients who in the opinion of the investigator are able to comply with the requirements of this study

Exclusion criteria:

  • Adverse events during the course of SNT-III-002(NCT00537680)which in the opinion of the investigator are attributable to idebenone and preclude further treatment with idebenone
  • Clinically significant abnormalities of clinical hematology or biochemistry including, but not limited to, elevations greater than 2 times the upper limit of normal of AST, ALT or creatinine
  • Treatment with coenzyme Q10, vitamin E (if taken at a dose 5 times above the daily requirement) or other sources of idebenone within the past month
  • Parallel participation in another clinical drug trial
  • Past or present history of abuse of drugs or alcohol
  • Pregnancy or breast-feeding
Sexes Eligible for Study: All
8 Years to 18 Years   (Child, Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Santhera Pharmaceuticals
Santhera Pharmaceuticals
Not Provided
Principal Investigator: Susan Perlman, MD University of California, Los Angeles
Principal Investigator: David Lynch, MD Children's Hospital of Philadelphia
Santhera Pharmaceuticals
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP